tirzepatide surpass cvot In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx SURPASS-CVOT trial: Tirzepatide was non-inferior

It stimulates collagen, improves microcirculation, reduces inflammation, and supports hair follicle regeneration, making it one of the most advanced therapies in regenerative dermatology

Gao X, Tian Y, Randell E, Zhou H, Sun G

Bai Y, Ma K, Li J, Li J, Bi C, Shan A (2021) Deoxynivalenol exposure induces liver damage in mice: inflammation and immune responses, oxidative stress, and protective effects of Lactobacillus rhamnosus GG

Retatrutide does not have a legitimate monthly retail price because it is investigational, not FDA-approved, and not commercially available

BPC-157: BPC-157 , , , ,

L-carnitine has been found to increase the likelihood of seizures in those who have had seizures previously